Paradigm Biocapital Advisors LP
Q4 2022 13F-HR Holdings
Net value change ($000)
+101,763
(13.6%)
New positions
4
Sold out positions
8
Turnover %
30.8%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q3 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Seagen Inc. | 36,791 | NEW |
| VOR | 36,064 | 531.8% |
| Horizon Therapeutics Public Ltd Co | 32,601 | 149.9% |
| ACLX | 27,327 | NEW |
| BIIB | 24,841 | 60.2% |
| SNDX | 23,666 | 90.8% |
| Karuna Therapeutics, Inc. | 20,870 | NEW |
| VRDN | 17,593 | 52.4% |
| INCY | 16,981 | 33.0% |
| ZLAB | 15,819 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| Global Blood Therapeutics, Inc. | -80,077 | -100.0% |
| AXSM | -23,206 | -100.0% |
| ESPR | -11,523 | -100.0% |
| Merus N.V. | -11,301 | -100.0% |
| G1 THERAPEUTICS INC | -11,048 | -100.0% |
| PRTA | -9,779 | -68.4% |
| OYST | -9,264 | -100.0% |
| TGTX | -8,912 | -100.0% |
| ASND | -8,268 | -16.1% |
| MIST | -5,828 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|